CollPlant

115 articles about CollPlant

• CollPlant to Present at ThinkEquity Conference on May 2, 2019 in New York City

  4/23/2019

  CollPlant, a regenerative medicine company, announced the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 10:00 am ET in the Lotus East room of the Mandarin Oriental Hotel in New York City.

• CollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics

  3/18/2019

  Distribution in Europe, Middle East, India and Africa for the treatment of tendinopathy

• Study Published in Wounds Journal Shows Remarkable Wound Closure Performance With CollPlant's VergenixFG in the Treatment of Chronic Wounds With a 94% Median Wound Area Reduction Within 4-weeks

  3/11/2019

  CollPlant, a regenerative medicine company, announced results from a clinical study conducted with its VergenixFG wound care product.

• CollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body

  2/19/2019

  Facility produces proprietary rhCollagen used for BioInks in 3D bioprinting of organs and for dermal fillers

• CollPlant Announces Appointment of Jonathan M.N. Rigby as Chairman of the Board

  2/4/2019

  CollPlant, a regenerative medicine company, announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately.

• CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

  11/12/2018

  Collaboration Combines CollPlant’s Proprietary rhCollagen-based BioInk Technology and United Therapeutics’ Regenerative Medicine and Organ Manufacturing Capabilities

• CollPlant to Ring Nasdaq Opening Bell on November 8, 2018

  11/7/2018

  CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringing the Nasdaq Stock Market Opening Bell on Thursday, November 8, 2018.

• CollPlant Shares Will Be Traded From Tuesday Oct 30 Exclusively on Nasdaq

  10/28/2018

  Last trading day on the Tel Aviv Stock Exchange (TASE) on October 29, 2018

• CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant

  10/22/2018

  Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities

• CollPlant Reports Second Quarter 2018 Financial Results and Provides Business Update

  9/21/2018

  CollPlant today announced financial results for the second quarter ended June 30, 2018 and provided an update on the Company's business developments.

• CollPlant Holdings to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

  8/28/2018

  CollPlant today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC.

• Dual-Listed CollPlant to Voluntarily Delist From Tel Aviv Stock Exchange

  8/8/2018

  CollPlant's American Depositary Shares to continue trading on the Nasdaq Capital Market

• CollPlant Appoints Dr. Wolfgang Ruttenstorfer to Its Board of Directors

  7/5/2018

  CollPlant announced the appointment of Dr. Wolfgang Ruttenstorfer to its board of directors, increasing the board to seven members.

• CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs

  6/26/2018

  CollPlant announced that it has received grant approval from the Israel Innovation Authority (IIA)

• CollPlant Appoints Professor Shay Soker from Wake Forest Institute for Regenerative Medicine to its Scientific Advisory Board

  6/19/2018

  Appointment of Shay Soker, Professor at the Wake Forest Institute for Regenerative Medicine (WFIRM), to its Scientific Advisory Board.

• CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update

  5/24/2018

  CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products

• CollPlant Announces Completion of the Third Closing of Alpha Investment

  5/1/2018

  CollPlant announced that it has completed the third and final closing of the investment agreement with Alpha Capital Anstalt.

• CollPlant Appoints Revital Mandil-Levin as Chief Business Development Officer

  4/12/2018

  CollPlant announced the appointment of Revital Mandil-Levin, PhD, MBA as Chief Business Development Officer, effective immediately.

• CollPlant Reports Fourth Quarter and Year End 2017 Financial Results and Provides Business Update

  3/21/2018

  CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products.

• CollPlant Joins ReMDO's Advanced Biomanufacturing Initiative for Development of a Universal BioInk for 3D Bioprinting of Tissues and Organs

  2/21/2018

  CollPlant announced that it is part of ReMDO's advanced biomanufacturing initiative for the development of a universal BioInk with tunable properties for 3D bioprinting of tissues and organs.